Literature DB >> 30409553

Surgery and Evidence-based Treatments in Patients with Newly Diagnosed High-grade Glioma.

Jennifer Serventi, Jacqueline Behr.   

Abstract

OBJECTIVE: To describe the currently accepted standard-of-care practice for surgical and medical management of newly diagnosed high-grade glioma. DATA SOURCES: Peer-reviewed journals, nationally accepted guidelines, and personal experience of the authors.
CONCLUSION: There is a widely accepted standard-of-care treatment protocol for patients with newly diagnosed high-grade glioma that includes maximal safe resection followed by radiation therapy with concurrent and adjuvant temozolomide. The regimen is well-tolerated and side effects are manageable. IMPLICATIONS FOR NURSING PRACTICE: Nurses who are involved in the care of patients with newly diagnosed high-grade glioma should be familiar with the regimen and its side effects to provide crucial patient and caregiver education in an accurate and beneficial manner.
Copyright © 2018. Published by Elsevier Inc.

Entities:  

Keywords:  GBM; Stupp regimen; glioblastoma; glioma; temozolomide

Mesh:

Year:  2018        PMID: 30409553     DOI: 10.1016/j.soncn.2018.10.009

Source DB:  PubMed          Journal:  Semin Oncol Nurs        ISSN: 0749-2081            Impact factor:   2.315


  7 in total

1.  Downregulation of circ_0037655 impedes glioma formation and metastasis via the regulation of miR-1229-3p/ITGB8 axis.

Authors:  Wenhui Zou; Yalei Cao; Kai Cheng; Changyu Li; Fu Zhu; Shumao Yang; Maolin Jin; Shaojun Song
Journal:  Open Life Sci       Date:  2021-05-10       Impact factor: 0.938

2.  Observation of the impact of the eight-step process combined with the four-track crossover quality control applied to patients with glioma surgery: a randomised trial.

Authors:  Zhen Zhang; Jing Ma; Ying Xu; Huihui Zhang
Journal:  Ann Transl Med       Date:  2021-04

3.  The impact of initial tumor microenvironment on imaging phenotype.

Authors:  Tavarekere N Nagaraja; Ana C deCarvalho; Stephen L Brown; Brent Griffith; Katelynn Farmer; Susan Irtenkauf; Laura Hasselbach; Abir Mukherjee; Seamus Bartlett; O Grahm Valadie; Glauber Cabral; Robert A Knight; Ian Y Lee; George W Divine; James R Ewing
Journal:  Cancer Treat Res Commun       Date:  2021-01-19

Review 4.  Enhancement of Therapies for Glioblastoma (GBM) Using Nanoparticle-based Delivery Systems.

Authors:  Kanawat Wiwatchaitawee; Juliana C Quarterman; Sean M Geary; Aliasger K Salem
Journal:  AAPS PharmSciTech       Date:  2021-02-11       Impact factor: 4.026

5.  A machine learning-based survival prediction model of high grade glioma by integration of clinical and dose-volume histogram parameters.

Authors:  Haiyan Chen; Chao Li; Lin Zheng; Wei Lu; Yanlin Li; Qichun Wei
Journal:  Cancer Med       Date:  2021-03-24       Impact factor: 4.452

6.  Influence of GSTP-1 Polymorphism on the Prognosis of Patients with High-Grade Glioma Who Received Temozolomide Plus Radiotherapy Adjuvant Treatment.

Authors:  De-Bao Zhi; Zhi-Yu Wang; Tong Xie; Wen-Wen Tu
Journal:  Int J Gen Med       Date:  2021-12-22

Review 7.  Use of MRI, metabolomic, and genomic biomarkers to identify mechanisms of chemoresistance in glioma.

Authors:  Cathy W Levenson; Thomas J Morgan; Pamela D Twigg; Timothy M Logan; Victor D Schepkin
Journal:  Cancer Drug Resist       Date:  2019-09-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.